National experts from the John Theurer Cancer Center will present 31 studies ... PhysOrg.com (press release) 269 - Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study, Andre Goy, MD, et al.. Oral Session: Dec. ... |
